NL-1|cas:188532-26-5|西域试剂

NL-1,99.72%

产品编号：Bellancom-135231| CAS NO：188532-26-5| 分子式：C₁₈H₂₅NO₃S| 分子量：335.46

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-135231		￥750.00	杭州北京（现货）
Bellancom-135231		￥2600.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

NL-1

产品介绍

NL-1 是一种具有抗白血病作用的 mitoNEET 抑制剂。NL-1 抑制 REH 和 REH/Ara-C 细胞生长，IC₅₀ 分别为 47.35 µM 和 56.26 µM。NL-1 介导的白血病细胞死亡需要激活自噬途径。

生物活性

NL-1 is a mitoNEET inhibitor with antileukemic effect. NL-1 inhibits REH and REH/Ara-C cells growth with IC₅₀s of 47.35 µM and 56.26 µM, respectively. NL-1-mediated death in leukemic cells requires the activation of the autophagic pathway.

体外研究

NL-1 (10-100 μM; 72 hours; REH, REH/Ara-C and ALL cell lines) treatment reduces the number of viable cells in REH, REH/Ara-C and ALL (SUP-B15, TOM-1, JM1, NALM-1, NALM-6, BV-173) cell lines, in a concentration-dependent manner. NL-1 inhibits SUPB15, NALM6 with IC₅₀s of 29.48 µM, 94.26 µM, respectively. TOM1, BV173, NALM1 and JM1 all have similar IC₅₀ values of around 60 µM for NL-1.
NL-1 (60 μM; 6 hours; REH, REH/Ara-C cell lines) treatment mediates autophagy, and inhibition of autophagy partially decreased NL-1-induced tumor cell death.
NL-1 pretreatment inhibits the chemotactic ability of both REH and REH/Ara-C cells to migrate towards multiple chemoattractants. The cells treated with NL1 shows a dose-dependent decrease in chemotaxis both in the REH and the REH/AraC cells.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Proliferation Assay

Cell Line:	REH, REH/Ara-C and ALL (SUP-B15, TOM-1, JM1, NALM-1, NALM-6, BV-173) cell lines
Concentration:	10 μM, 20 μM, 30 μM, 40 μM, 50 μM, 60 μM, 70 μM, 80 μM, 100 μM
Incubation Time:	72 hours
Result:	Reduced the number of viable cells in REH, REH/Ara-C and ALL (SUP-B15, TOM-1, JM1, NALM-1, NALM-6, BV-173) cell lines, in a concentration-dependent manner.

Cell Autophagy Assay

Cell Line:	REH, REH/Ara-C cell lines
Concentration:	60 μM
Incubation Time:	6 hours
Result:	Induced cell autophagy.

体内研究
(In Vivo)

NL-1 (10 mg/kg; intraperitoneal injection; daily; for 5 days; female NSG mice) treatment shows antileukemic activity in an in vivo mouse ALL model.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	10 female NOD.Cg-Prkdc^scid Il2rg^tm1Wjl/SzJ (NSG) mice (6-8 month old) injected with TOM-1 ALL cells
Dosage:	10 mg/kg
Administration:	Intraperitoneal injection; daily; for 5 days
Result:	Showed antileukemic activity in an in vivo mouse ALL model.

体内研究

NL-1 (10 mg/kg; intraperitoneal injection; daily; for 5 days; female NSG mice) treatment shows antileukemic activity in an in vivo mouse ALL model.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	10 female NOD.Cg-Prkdc^scid Il2rg^tm1Wjl/SzJ (NSG) mice (6-8 month old) injected with TOM-1 ALL cells
Dosage:	10 mg/kg
Administration:	Intraperitoneal injection; daily; for 5 days
Result:	Showed antileukemic activity in an in vivo mouse ALL model.

体内研究

NL-1 (10 mg/kg; intraperitoneal injection; daily; for 5 days; female NSG mice) treatment shows antileukemic activity in an in vivo mouse ALL model.

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	10 female NOD.Cg-Prkdc^scid Il2rg^tm1Wjl/SzJ (NSG) mice (6-8 month old) injected with TOM-1 ALL cells
Dosage:	10 mg/kg
Administration:	Intraperitoneal injection; daily; for 5 days
Result:	Showed antileukemic activity in an in vivo mouse ALL model.

性状

Solid

溶解性数据

In Vitro:

DMSO : 250 mg/mL (745.25 mM; Need ultrasonic)

配制储备液

浓度溶剂体积质量	1 mg	5 mg	10 mg

1 mM	2.9810 mL	14.9049 mL	29.8098 mL
5 mM	0.5962 mL	2.9810 mL	5.9620 mL
10 mM	0.2981 mL	1.4905 mL	2.9810 mL

请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。
储备液的保存方式和期限：-80°C, 6 months; -20°C, 1 month。-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。

In Vivo:

请根据您的实验动物和给药方式选择适当的溶解方案。以下溶解方案都请先按照 In Vitro 方式配制澄清的储备液，再依次添加助溶剂：

——为保证实验结果的可靠性，澄清的储备液可以根据储存条件，适当保存；体内实验的工作液，建议您现用现配，当天使用；以下溶剂前显示的百
分比是指该溶剂在您配制终溶液中的体积占比；如在配制过程中出现沉淀、析出现象，可以通过加热和/或超声的方式助溶

1.

请依序添加每种溶剂： 10% DMSO 40% PEG300 5% Tween-80 45% saline
Solubility: ≥ 2.08 mg/mL (6.20 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (6.20 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 400 μL PEG300 中，混合均匀；向上述体系中加入50 μL Tween-80，混合均匀；然后继续加入 450 μL生理盐水定容至 1 mL。
将 0.9 g 氯化钠，完全溶解于 100 mL ddH₂O 中，得到澄清透明的生理盐水溶液
2.

请依序添加每种溶剂： 10% DMSO 90% (20% SBE-β-CD in saline)
Solubility: ≥ 2.08 mg/mL (6.20 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (6.20 mM，饱和度未知) 的澄清溶液。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL 20% 的 SBE-β-CD 生理盐水水溶液中，混合均匀。
将 2 g 磺丁基醚 β-环糊精加入 5 mL 生理盐水中，再用生理盐水定容至 10 mL，完全溶解，澄清透明
3.

请依序添加每种溶剂： 10% DMSO 90% corn oil
Solubility: ≥ 2.08 mg/mL (6.20 mM); Clear solution

此方案可获得 ≥ 2.08 mg/mL (6.20 mM，饱和度未知) 的澄清溶液，此方案不适用于实验周期在半个月以上的实验。
以 1 mL 工作液为例，取 100 μL 20.8 mg/mL 的澄清 DMSO 储备液加到 900 μL玉米油中，混合均匀。